AN2 Therapeutics, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Menlo Park, CA
SEC filing record 1 source field available
Fiscal year end
31 December
AN2 Therapeutics, Inc. has filed 378 SEC EDGAR filings since 24 Sep 2021

SEC filing history

Showing 326-350 of 378 matching filings.

Per page
25
Current page
14
4

FORM 4 SUBMISSION

Filing date
16 May 2022
Reporting date
12 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 May 2022
Reporting date
12 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 May 2022
Reporting date
12 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 May 2022
Reporting date
12 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 May 2022
Reporting date
12 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
09 May 2022
Reporting date
05 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
09 May 2022
Reporting date
05 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-41331

8-K

Filing date
09 May 2022
Reporting date
05 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-93617

AN2 THERAPEUTICS, INC.

Filing date
08 Apr 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-93617

AN2 THERAPEUTICS, INC.

Filing date
08 Apr 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-93617

THE SCHEDULE 13G

Filing date
04 Apr 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
31 Mar 2022
Reporting date
29 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
31 Mar 2022
Reporting date
29 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
31 Mar 2022
Reporting date
29 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
31 Mar 2022
Reporting date
29 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
31 Mar 2022
Reporting date
29 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
31 Mar 2022
Reporting date
29 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 File 333-263917

S-8

Filing date
29 Mar 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
424B4 File 333-263295

424B4

Filing date
28 Mar 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SEC STAFF LETTER

SEC STAFF LETTER filing

Filing date
24 Mar 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-263295

EFFECT filing

Filing date
24 Mar 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-1MEF File 333-263840

S-1MEF

Filing date
24 Mar 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
24 Mar 2022
Reporting date
24 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .